{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:57:20Z","timestamp":1792483040456,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012482","name":"University of Michigan Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["P30-CA-046592"],"award-info":[{"award-number":["P30-CA-046592"]}],"id":[{"id":"10.13039\/100012482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA216919"],"award-info":[{"award-number":["R01 CA216919"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA173292"],"award-info":[{"award-number":["R01 CA173292"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["3U01 CA120458"],"award-info":[{"award-number":["3U01 CA120458"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.surg.2021.04.049","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T17:26:47Z","timestamp":1627925207000},"page":"119-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Identification of novel lipid metabolic biomarkers associated with poor adrenocortical carcinoma prognosis using integrated bioinformatics"],"prefix":"10.1016","volume":"171","author":[{"given":"Chitra","family":"Subramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2021.04.049_bib1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?","volume":"30","author":"Kebebew","year":"2006","journal-title":"World J Surg"},{"key":"10.1016\/j.surg.2021.04.049_bib2","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1210\/jc.2008-2291","article-title":"Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review","volume":"94","author":"Golden","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2021.04.049_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.surg.2021.04.049_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ecl.2018.02.003","article-title":"Adrenocortical carcinoma with hypercortisolism","volume":"47","author":"Puglisi","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.surg.2021.04.049_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","article-title":"Clinical management of adrenocortical carcinoma","volume":"23","author":"Fassnacht","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2021.04.049_bib6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.surg.2018.04.068","article-title":"Longitudinal patterns of recurrence in patients with adrenocortical carcinoma","volume":"165","author":"Glenn","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2021.04.049_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12672-020-00385-3","article-title":"Advanced adrenocortical carcinoma (ACC): a review with focus on second-line therapies","volume":"11","author":"Ardolino","year":"2020","journal-title":"Horm Cancer"},{"key":"10.1016\/j.surg.2021.04.049_bib8","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1210\/jc.2013-3020","article-title":"Update in adrenocortical carcinoma","volume":"98","author":"Fassnacht","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2021.04.049_bib9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1186\/s12885-017-3506-z","article-title":"Outcome after resection of adrenocortical carcinoma liver metastases: a retrospective study","volume":"17","author":"Baur","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.surg.2021.04.049_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.addr.2020.07.013","article-title":"Lipids and cancer: emerging roles in pathogenesis, diagnosis and therapeutic intervention","volume":"159","author":"Butler","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.surg.2021.04.049_bib11","doi-asserted-by":"crossref","first-page":"577420","DOI":"10.3389\/fonc.2020.577420","article-title":"Alterations of lipid metabolism in cancer: implications in prognosis and treatment","volume":"10","author":"Fernandez","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.surg.2021.04.049_bib12","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1158\/1078-0432.CCR-07-1186","article-title":"Selective inhibition of fatty acid synthase for lung cancer treatment","volume":"13","author":"Orita","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"Suppl 7","key":"10.1016\/j.surg.2021.04.049_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12859-019-2734-4","article-title":"Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data","volume":"20","author":"Hao","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.surg.2021.04.049_bib14","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1038\/oncsis.2015.49","article-title":"Lipid metabolic reprogramming in cancer cells","volume":"5","author":"Beloribi-Djefaflia","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.surg.2021.04.049_bib15","first-page":"5488","article-title":"Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis","volume":"50","author":"Gazdar","year":"1990","journal-title":"Cancer Res"},{"issue":"D1","key":"10.1016\/j.surg.2021.04.049_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw937","article-title":"The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible","volume":"45","author":"Szklarczyk","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.surg.2021.04.049_bib17","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1210\/js.2018-00197","article-title":"Therapeutic targets for adrenocortical carcinoma in the genomics era","volume":"2","author":"Mohan","year":"2018","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.surg.2021.04.049_bib18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/jc.2008-1456","article-title":"Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma","volume":"94","author":"Barlaskar","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2021.04.049_bib19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","article-title":"Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma","volume":"65","author":"Haluska","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.surg.2021.04.049_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","article-title":"The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial","volume":"5","author":"Lerario","year":"2014","journal-title":"Horm Cancer"},{"key":"10.1016\/j.surg.2021.04.049_bib21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2021.04.049_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assie","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.surg.2021.04.049_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ccell.2016.07.013","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"30","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.surg.2021.04.049_bib24","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1242\/dmm.011338","article-title":"Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development","volume":"6","author":"Baenke","year":"2013","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.surg.2021.04.049_bib25","doi-asserted-by":"crossref","first-page":"105730","DOI":"10.1016\/j.jsbmb.2020.105730","article-title":"Sphingosine-1-phosphate lyase (SGPL1) deficiency is associated with mitochondrial dysfunction","volume":"202","author":"Maharaj","year":"2020","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.surg.2021.04.049_bib26","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2217\/fon.10.116","article-title":"Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance","volume":"6","author":"Ponnusamy","year":"2010","journal-title":"Future Oncol"},{"key":"10.1016\/j.surg.2021.04.049_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1634\/theoncologist.2010-0270","article-title":"Current and emerging therapies for advanced adrenocortical carcinoma","volume":"16","author":"Tacon","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.surg.2021.04.049_bib28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/bs.acr.2018.04.016","article-title":"Novel sphingolipid-based cancer therapeutics in the personalized medicine era","volume":"140","author":"Shaw","year":"2018","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.surg.2021.04.049_bib29","doi-asserted-by":"crossref","first-page":"100926","DOI":"10.1016\/j.tranon.2020.100926","article-title":"Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models","volume":"14","author":"Rupp","year":"2021","journal-title":"Transl Oncol"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606021005547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606021005547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:28:27Z","timestamp":1778632107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606021005547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0039606021005547"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2021.04.049","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of novel lipid metabolic biomarkers associated with poor adrenocortical carcinoma prognosis using integrated bioinformatics","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2021.04.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}